Subscribe: Merck.com - Corporate News
http://www.merck.com/rss/corporate.xml
Preview: Merck.com - Corporate News

Corporate News





 



KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Wed, 07 Dec 2016 07:45:00 +0000

Dateline City:
KENILWORTH, N.J.

First Presentation of Patient-Reported Outcomes from KEYNOTE-024 Study of Patients with Metastatic NSCLC Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More)

Findings Presented in Plenary Session at 17 th World Conference on Lung Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive health-related quality of life (HRQoL) findings from an exploratory analysis from the phase 3 KEYNOTE-024 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, compared to standard of care (SOC) platinum-containing chemotherapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (tumor proportion score [TPS] of

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer

Tue, 06 Dec 2016 13:20:00 +0000

Dateline City:
KENILWORTH, N.J.

Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028

Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients.

Language:
English
Contact:

Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investors
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck to Participate at the Citi 2016 Global Healthcare Conference

Tue, 06 Dec 2016 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, is scheduled to participate at the Citi 2016 Global Healthcare Conference in New York on Dec. 7, 2016 at 12:35 p.m. EST.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology

Tue, 06 Dec 2016 00:30:00 +0000

Dateline City:
KENILWORTH, N.J.

Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent

With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding Patients

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Updated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology

Mon, 05 Dec 2016 15:42:00 +0000

Dateline City:
KENILWORTH, N.J.

Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with follow-up of up to 27 months in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma, who were ineligible for or failed to respond to autologous stem-cell transplantation (ASCT).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s KEYTRUDA® (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma

Thu, 01 Dec 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of therapy.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies

Wed, 30 Nov 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments

Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary Session

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec.

Language:
English
Contact:

Media Contacts:
Pamela Eisele, (267) 305-3558
or
Kim Hamilton, (908) 740-1863
or
Investor Contacts:
Teri Loxam, (908) 740-1986
or
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action.

Tue, 29 Nov 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Young to Help Educate on the Importance of Biomarker Testing in Non-Small Cell Lung Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--Acclaimed actress and singer Bellamy Young lost her father to lung cancer, and she is now sharing her personal experience as part of Test. Talk. Take Action., a new awareness campaign focused on increasing people’s understanding of biomarkers and the role they play in the treatment of non-small cell lung cancer (NSCLC).

Language:
English
Contact:

Media
Merck
Courtney Ronaldo, 908-236-1108
or
Christiana Pascale, 212-257-6722

Media Capsule:
(object)

iframes are not supported by your browser.

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA® (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer

Mon, 28 Nov 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of previously treated patients with advanced microsatellite instability-high (MSI-H) cancer.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Increased Quarterly Dividend

Tue, 22 Nov 2016 18:22:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company’s quarterly dividend to $0.47 per outstanding share of the company’s common stock, up $0.01 from $0.46 per outstanding share paid last quarter. Payment will be made on Jan. 9, 2017, to stockholders of record at the close of business on Dec. 15, 2016.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology

Tue, 22 Nov 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral Presentations

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with a range of blood cancers including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, will be presented at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Dec. 3-6.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities

Thu, 17 Nov 2016 14:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes Care

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the Foundation over five years, Bridging the Gap will build sustainable partnerships across sectors to support innovative approaches to diabetes treatment and management.

Language:
English
Contact:

Merck
Lainie Keller, 908-236-5036
or
Jeanine Clemente, 908-236-5059

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

Sun, 13 Nov 2016 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the company’s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3).

Language:
English
Contact:

Media:
Doris Li, 908-246-5701
or
Sarra Herzog, 201-669-6570
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer

Sat, 12 Nov 2016 16:45:00 +0000

Dateline City:
KENILWORTH, N.J.

First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer’s (SITC) 31 st Annual Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced bladder (urothelial) cancer previously treated with platinum-containing chemotherapy. As previously announced, KEYTRUDA was superior to investigator-choice chemotherapy for the primary endpoint of overall survival (OS) in this phase 3 study, and was stopped early.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting®

Sat, 12 Nov 2016 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the use of ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or GT4-infected patient populations, including those who receive opioid agonist therapy (OAT), are infected with chronic HCV GT1b, use proton pump inhibitors (PPIs) or have moderate kidney disease.

Language:
English
Contact:

Merck
Media:
Doris Li, (908) 246-5701
Sarra Herzog, (201) 669-6570
or
Investor:
Teri Loxam, (908) 740-1986
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

Mon, 07 Nov 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting, Nov. 9-13.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine

Wed, 02 Nov 2016 20:30:00 +0000

Dateline City:
KENILWORTH, N.J.

Results of First Phase 3 Trial Anticipated in Late 2017

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer’s disease (AD).

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
or
Ian McConnell, 908-740-1921
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Prices EUR 1.0 Billion Debt Offering

Wed, 26 Oct 2016 17:31:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, priced today a EUR 1.0 billion public offering of two series of Euro-denominated senior unsecured notes (collectively, the “New Notes”). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0 billion equates to approximately $1.087 billion. The notes include:

EUR 500 million of 0.500% notes due Nov. 2024
EUR 500 million of 1.375% notes due Nov. 2036

Language:
English
Contact:

Merck & Co., Inc.
Media:
Lainie Keller, 908-236-5036
Tracy Ogden, 267-305-2301
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016

Wed, 26 Oct 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will provide more than 30 scientific data presentations on the company’s established and investigational infectious disease medicines and vaccines at ID Week 2016 in New Orleans from Oct. 26-30.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Robert Consalvo, 908-295-0928
Skip Irvine, 215-652-6059
or
Investors:
Amy Klug, 908-740-1898
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Third-Quarter 2016 Financial Results

Tue, 25 Oct 2016 10:45:00 +0000

Dateline City: KENILWORTH, N.J. Third-Quarter 2016 Worldwide Sales Were $10.5 Billion, an Increase of 5 Percent, Including a 1 Percent Negative Impact from Foreign Exchange Third-Quarter 2016 GAAP EPS Was $0.78; Third-Quarter Non-GAAP EPS Was $1.07 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS to be Between $2.02 and $2.09; Full-Year 2016 Non-GAAP EPS to be Between $3.71 and $3.78 Advanced KEYTRUDA Development Program FDA Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) New Data Were Included in Labeling for KEYTRUDA Showing Improved Survival Compared to Chemotherapy in Previously Treated Patients with NSCLC Whose Tumors Express PD-L1 (TPS of 1 Percent or More) FDA Approved KEYTRUDA to Treat Previously Treated Recurrent or Metastatic Head and Neck Cancer KEYNOTE-045 Study Evaluating KEYTRUDA in Previously Treated Advanced Bladder Cancer (Urothelial Cancer) Met Primary Endpoint of Overall Survival and Stopped Early KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more[...]



FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations

Mon, 24 Oct 2016 22:04:00 +0000

Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more[...]



FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence

Sat, 22 Oct 2016 01:57:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZINPLAVA™ (bezlotoxumab) Injection 25 mg/mL. Merck anticipates making ZINPLAVA available in first quarter 2017.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Robert Consalvo, 908-236-1127
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

Fri, 21 Oct 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.

KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint

Wed, 19 Oct 2016 11:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint.

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
Robert Consalvo, 908-236-1127
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Microbiology

Mon, 17 Oct 2016 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Merck Research Laboratories (MRL) facilities in Rahway, N.J., and West Point, Pa., have been designated as “Milestones in Microbiology” sites by the American Society for Microbiology (ASM) for their contributions to anti-infectives and vaccines, respectively. This is the first time a biopharmaceutical company has received this recognition.

Language:
English
Contact:

Media:
Pam Eisele, 267-305-3558
Ian McConnell, 908-740-1921
Investor:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more